Enzo Biochem (ENZ)

[mlkrborn]

Recent financials: Still has $15 m cash:

"Enzo Q3 Revenues Flat, Net Loss Widens
June 11, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Monday that revenues for the fiscal third quarter inched up slightly year over year, but that net loss increased.

During the three months ended April 30, the New York-based company recorded $25.9 million in revenues, up from $25.8 million in the year-ago period. Clinical laboratory services increased to $15.2 million, up 10percent from $13.8 million, but product revenues slid 12 percent to $9.6 million from $10.9 million. Royalty and licensing fees were essentially flat at $1.1 million.

In its Form 10-Q filed with the US Securities and Exchange Commission, Enzo said that R&D costs shrank 24 percent year over year to $1.6 million from $2.1 million, while SG&A costs grew 9 percent to $11.9 million from $10.9 million a year ago.

Enzo's net loss for the third quarter was $3.4 million, or $.09 per share, compared to a net loss of $2.1 million, or $.05 per share, a year ago.

The company finished the quarter with $15.3 million in cash, cash equivalents, and short-term investments. "